Analysts Expect Iovance Biotherapeutics Inc (NASDAQ:IOVA) to Announce -$0.46 EPS

Analysts expect Iovance Biotherapeutics Inc (NASDAQ:IOVA) to post earnings per share (EPS) of ($0.46) for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Iovance Biotherapeutics’ earnings, with estimates ranging from ($0.50) to ($0.42). Iovance Biotherapeutics reported earnings per share of ($0.40) during the same quarter last year, which would indicate a negative year-over-year growth rate of 15%. The company is expected to issue its next quarterly earnings report on Monday, November 2nd.

According to Zacks, analysts expect that Iovance Biotherapeutics will report full year earnings of ($1.94) per share for the current financial year, with EPS estimates ranging from ($2.05) to ($1.79). For the next financial year, analysts expect that the business will post earnings of ($2.14) per share, with EPS estimates ranging from ($2.70) to ($1.69). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that cover Iovance Biotherapeutics.

Iovance Biotherapeutics (NASDAQ:IOVA) last announced its quarterly earnings results on Thursday, August 6th. The biotechnology company reported ($0.47) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.52) by $0.05.

A number of research analysts recently issued reports on the stock. BidaskClub upgraded shares of Iovance Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, September 1st. Chardan Capital raised their target price on shares of Iovance Biotherapeutics from $44.00 to $53.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Zacks Investment Research lowered shares of Iovance Biotherapeutics from a “buy” rating to a “hold” rating and set a $33.00 target price on the stock. in a research note on Tuesday, August 4th. Finally, Oppenheimer reiterated a “buy” rating and issued a $43.00 target price on shares of Iovance Biotherapeutics in a research note on Friday, August 7th. Two analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $46.73.

Large investors have recently added to or reduced their stakes in the company. Lindbrook Capital LLC bought a new position in shares of Iovance Biotherapeutics during the 2nd quarter worth about $27,000. Citizens Financial Group Inc RI bought a new position in shares of Iovance Biotherapeutics during the 2nd quarter worth about $27,000. Advisors Asset Management Inc. bought a new position in shares of Iovance Biotherapeutics during the 2nd quarter worth about $80,000. US Bancorp DE lifted its holdings in shares of Iovance Biotherapeutics by 74.7% during the 1st quarter. US Bancorp DE now owns 3,688 shares of the biotechnology company’s stock worth $110,000 after acquiring an additional 1,577 shares during the period. Finally, Point72 Hong Kong Ltd bought a new position in Iovance Biotherapeutics during the 2nd quarter valued at about $110,000. 95.15% of the stock is owned by institutional investors.

NASDAQ:IOVA traded up $0.38 during midday trading on Tuesday, reaching $32.30. The stock had a trading volume of 25,617 shares, compared to its average volume of 1,731,123. Iovance Biotherapeutics has a 1-year low of $17.67 and a 1-year high of $41.49. The firm’s fifty day simple moving average is $31.26 and its 200-day simple moving average is $31.18. The stock has a market capitalization of $4.67 billion, a P/E ratio of -16.71 and a beta of 1.03.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is lifileucel, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of metastatic melanoma.

Read More: Understanding dividend yield and dividend payout ratio

Get a free copy of the Zacks research report on Iovance Biotherapeutics (IOVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Iovance Biotherapeutics (NASDAQ:IOVA)

Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.